Author + information
- Lilei Yu,
- Liping Zhou,
- Bing Huang,
- Zhuo Wang,
- Songyun Wang,
- Menglong Wang,
- Xuefei Li,
- Guannan Meng,
- Shenxu Yuan,
- Yuhong Wang,
- Xiaoya Zhou and
- Hong Jiang
Background: Studies have shown that left stellate ganglion (LSG) ablation protects against myocardial ischemia related ventricular arrhythmias (VAs). Optogenetics is a transient, precise and controllable method and has been widely used in neuroscience to regulate the activity of neurons. This study aimed to investigate whether optogenetically silencing LSG neural activity could suppress ischemia related VAs.
Methods: Canines were divided into optogenetics group (AAV2/9-CAG-ArchT-GFP injected into LSG) and control group (AAV2/9-CAG-GFP injected into LSG). After four weeks, LSG function and neural activity, ventricular action potential duration (APD) and effective refractory period (ERP) were measured in the absence or presence of LED illumination (565nm). ECG after ischemia was recorded for VAs analysis. The expression of NGF and c-fos in LSG was evaluated.
Results: In optogenetics group, transient and thirty minutes of sustained optogenetic modulation significantly decreased LSG function and neural activity, prolonged ERP and APD90. However, no significant changes were observed in control group. Furthermore, optogenetic modulation attenuated ischemia induced increase in LSG neural activity and decrease in ERP and APD90. In addition, the ischemia-induced VAs was significantly reduced and the expression of NGF and c-fos were down-regulated by optogenetic approach.
Conclusions: Optogenetic approach might silence LSG neural activity, thereby suppressing ischemia-induced VAs.
Room 146 A
Saturday, March 18, 2017, 8:12 a.m.-8:22 a.m.
Session Title: Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review
Abstract Category: 4. Arrhythmias and Clinical EP: Basic
Presentation Number: 901-04
- 2017 American College of Cardiology Foundation